๐Ÿฅ VAERS Vaccine Data Browser

๐Ÿ”’ Privacy & Data Disclaimer

About This Site

This is a public data browser for the Vaccine Adverse Event Reporting System (VAERS). By using this site, you acknowledge and agree to the following:

Data Source & Accuracy

  • Public Data: All data displayed comes from the publicly available VAERS database maintained by the CDC and FDA.
  • No Verification: VAERS accepts all reports without verifying medical accuracy. Reports do not prove causation between vaccines and adverse events.
  • Anyone Can Report: Healthcare providers, patients, family members, and anyone else can submit reports to VAERS.
  • Research Purpose: This data is for transparency, research, and monitoring vaccine safety signals only.

Your Privacy

  • No Personal Data Collection: This site does not collect, store, or track any personal information about visitors.
  • No Cookies: We do not use cookies except for remembering that you've seen this disclaimer (stored locally in your browser).
  • No Analytics: We do not use Google Analytics or any other tracking services.
  • Search Privacy: Your searches and filters are not logged or stored on our servers.
  • Public Data Only: The VAERS data shown here is already public and contains no personally identifiable information.

Medical Disclaimer

  • Not Medical Advice: This tool is for informational purposes only and does not provide medical advice.
  • Consult Healthcare Providers: Always consult qualified healthcare professionals for medical decisions.
  • No Liability: We are not responsible for decisions made based on this data.

Data Interpretation

  • The presence of a report does not mean the vaccine caused the adverse event.
  • Coincidental events are often reported (e.g., a heart attack that happened to occur after vaccination).
  • Serious adverse events must be reported by law, even if unrelated to the vaccine.
  • The database is useful for detecting safety signals that require further investigation.

๐Ÿ“– Help & Search Guide

Column Icons Legend

๐Ÿ’€ Death
๐Ÿฅ Hospitalized
๐Ÿš‘ Emergency Room
โ™ฟ Disability
โš ๏ธ Life Threatening

How to Search

๐Ÿ’ก Search Tips:
  • Select Year: Choose a specific year OR "All Years" to search across all data
  • All Years requires filters: When searching all years, you must select at least one filter (lot number, vaccine type, outcome, etc.) for performance
  • Lot number tracking: Use "All Years" + Lot Number to track lots across multiple years
  • Combine filters: Use multiple filters together to narrow results (e.g., Age + Vaccine Type + Death)
  • VAERS ID: Search for specific report by ID number
  • Age: Enter exact age (e.g., 25) or decimal (e.g., 0.5 for 6 months)
  • State: Enter 2-letter state code (e.g., CA, NY, TX)
  • Vaccine Type: Search partial names (e.g., "COVID19", "FLU", "HPV")
  • Manufacturer: Search by company (e.g., "PFIZER", "MODERNA")
  • Lot Number: Search specific vaccine lot (works great with "All Years")
  • Symptoms: Search for any symptom keyword (e.g., "fever", "rash")
  • Death/Hospitalized: Filter to only show cases with these outcomes

Understanding the Data

  • Reports are unverified: VAERS accepts all reports without medical verification
  • Not proof of causation: A report does not mean the vaccine caused the event
  • Anyone can report: Healthcare providers, patients, and family members can submit reports
  • Multiple vaccines: One report may list multiple vaccines given at the same time
  • Blank fields: Not all fields are required, so some data may be missing

Using the Table

  • Sort columns: Click column headers (ID, Age, Sex, Date, Died) to sort
  • Expand text: Click "More" to see full narrative or symptom text
  • Navigate pages: Use pagination controls at top and bottom of table
  • Export results: Click "๐Ÿ“ฅ Export CSV" to download filtered data (max 10,000 records)

๐Ÿ’ก Frequently Asked Questions (FAQ)

What is this site?

๐Ÿฅ VAERS Vaccine Data Browser is an independent, third-party data browser for publicly available VAERS (Vaccine Adverse Event Reporting System) data.

Important: This site is NOT affiliated with, endorsed by, or operated by the CDC, FDA, or any government agency. We are an independent service that makes public VAERS data easier to search and analyze.

What is VAERS?

VAERS (Vaccine Adverse Event Reporting System) is a national early warning system established in 1990 to detect possible safety problems with vaccines. It's co-managed by the CDC (Centers for Disease Control and Prevention) and FDA (Food and Drug Administration).

VAERS accepts and analyzes reports of adverse events (possible side effects) after a person has received a vaccination.

Official VAERS website: vaers.hhs.gov

Is this data HIPAA compliant?

Yes, absolutely. All VAERS data displayed here is:

  • Publicly available - Published by the CDC/FDA on their official website
  • De-identified - Contains no personally identifiable information (names, addresses, contact info removed)
  • Legally accessible - Available to researchers, media, and the general public under FOIA (Freedom of Information Act)
  • Not protected health information - Once de-identified and published by the government, it's no longer covered by HIPAA restrictions

This site displays the same public data available at vaers.hhs.gov/data.

Why does this site exist?

We believe in transparency and public access to health data. While the CDC/FDA provide VAERS data, their official site:

  • Is difficult to search and filter
  • Requires downloading large CSV files and technical knowledge
  • Is not user-friendly for the average person

This independent site makes the same publicly available data easier to search, filter, and understand for researchers, journalists, healthcare workers, and concerned citizens.

Where does the data come from?

All data is downloaded directly from the official CDC/FDA VAERS website at vaers.hhs.gov/data.

The data is:

  • Publicly released by the CDC/FDA every week
  • Available as downloadable CSV files
  • Imported into this site's database for easier searching
  • Displayed exactly as provided (no modifications or filtering)

This site does not collect, modify, or add to the official VAERS data.

My vaccine lot number matches one with deaths/serious events - should I be worried?

Important context:

  • VAERS reports do NOT prove causation - A report means an event occurred after vaccination, but doesn't mean the vaccine caused it
  • Anyone can report - Reports are not verified for medical accuracy before being published
  • Coincidences happen - When millions of people get vaccinated, some will experience unrelated medical events afterward
  • Large lot numbers - Popular vaccines may have hundreds of thousands of doses from one lot number
  • More vaccinations = more reports - Lots used widely will naturally have more reports

What to do:

  • Don't panic - VAERS data requires expert analysis to interpret
  • Talk to your doctor if you have concerns
  • Check official CDC/FDA safety communications for genuine safety signals
  • Remember: billions of vaccine doses have been safely administered

Can I trust VAERS data?

VAERS is valuable but has limitations:

Strengths:

  • โœ… Early warning system for potential safety signals
  • โœ… Open and transparent - publicly accessible
  • โœ… Accepts all reports regardless of likelihood of causation
  • โœ… Monitored by CDC/FDA experts who investigate concerning patterns

Limitations:

  • โš ๏ธ Reports are unverified - not investigated before publication
  • โš ๏ธ Cannot determine if vaccine caused the event
  • โš ๏ธ Underreporting - not all adverse events are reported
  • โš ๏ธ Overreporting - coincidental events may be reported
  • โš ๏ธ Incomplete data - not all fields are required

Bottom line: VAERS is an important tool for safety monitoring, but individual reports should not be used as proof that a vaccine caused harm.

What are "adverse events"?

An adverse event is any undesirable health occurrence that happens after vaccination, including:

  • Common reactions: Sore arm, mild fever, fatigue (usually expected)
  • Serious events: Hospitalization, disability, life-threatening illness, death
  • Coincidental events: Medical conditions that would have occurred anyway

Important: An adverse event doesn't mean the vaccine caused it - only that it occurred after vaccination. Many reported events are coincidental or unrelated.

Why are some lot numbers listed multiple times?

This is normal and expected! A person may receive multiple doses of the same vaccine from the same lot number:

  • COVID vaccines require 2-3 doses
  • HPV, Hepatitis B, and other vaccines have multi-dose schedules
  • Each dose is recorded as a separate entry

Example: Person receives Pfizer COVID dose 1 (lot ABC123) and dose 2 (lot ABC123) - lot ABC123 appears twice in their report.

How often is this data updated?

The CDC/FDA releases new VAERS data every Friday. This site is typically updated:

  • Weekly or bi-weekly for recent data
  • Check the available years to see what data is currently loaded
  • During updates, the site may be in maintenance mode temporarily

Where can I learn more?

โš ๏ธ DISCLAIMER: This data is from the Vaccine Adverse Event Reporting System (VAERS). Reports do not establish causation between vaccines and adverse events. Anyone can submit a report, and reports are not verified. This is raw data for transparency and research purposes only.
34,052
Total Reports (2025)
500
Deaths Reported
1,634
Hospitalizations
30
ER Visits
1,191
Disabilities
570
Life Threatening
๐Ÿ”„ Reset ๐Ÿ“ฅ Export CSV
ID Age Sex State Date โ–ผ Onset Days Vaccine Manufacturer Lot # Symptoms Narrative ๐Ÿ’€ ๐Ÿฅ ๐Ÿš‘ โ™ฟ โš ๏ธ
2840171 51 F OR 05/08/2025 TDAP
 GLAXOSMITHKLINE BIOLOGICALS
 3RE73
No adverse event No adverse event
No adverse events or sx. No treatment needed No adverse events or sx. No treatment needed
2840172 0.33 M 05/08/2025 PNC20
RV5
 PFIZER\WYETH
MERCK & CO. INC.
 MF0415
2096663
Tremor; Tremor Tremor; Tremor
per mom, eyes closed and tremor for 15 sec while breastfeeding per mom, eyes closed and tremor for 15 sec while breastfeeding
2840173 69 M VA 05/08/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
Headache, Herpes zoster, Nausea, Rash Headache, Herpes zoster, Nausea, Rash
I got the shingles. Headache, nausea, rash on left buttocks extending down to upper hamstring area.... I got the shingles. Headache, nausea, rash on left buttocks extending down to upper hamstring area. Took valACYclovir (VALTREX) 21 pills over 7 days. More
2839814 NJ 05/07/2025 VARCEL
VARCEL
 MERCK & CO. INC.
MERCK & CO. INC.
 Y014868
No adverse event, Product storage error; No adverse event, Product storage error No adverse event, Product storage error; No adverse event, Product storage error
No additional AEs; patient received improperly stored vaccine; This spontaneous report was received ... No additional AEs; patient received improperly stored vaccine; This spontaneous report was received from a certified medical assistant (CMA) on 28-APR-2025 and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions were not reported, and concomitant therapies were not reported. 24-APR-2025, the patient was vaccinated with an improper stored dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Y014868, expiration date: 03-SEP-2026), dose/frequency was reported as 1 dose, and sterile diluent (lot #, dose, route o administration not reported) for prophylaxis (Product storage error). The administered dose of the vaccine experienced a temperature excursion 5.5 Fahrenheit up to 14.4 Fahrenheit for 40 minutes and 14.5 Fahrenheit up to 46.4 Fahrenheit for 10 minutes, with no previous temperature excursion reported. No adverse vent reported. More
2839815 NM 05/07/2025 HPV9
 MERCK & CO. INC.
 Y012508
No adverse event, Product storage error No adverse event, Product storage error
No additional AE reported.; patient was administered GARDASIL9 during a temperature excursion.; This... No additional AE reported.; patient was administered GARDASIL9 during a temperature excursion.; This spontaneous report was received from a health care business professional and refers to a patient of unknown age and gender. The patient's medical, concurrent conditions were not reported, and concomitant therapies were not reported. On 28-APR-2025, the patient was vaccinated with an improper storage dose of dose of Human Papillomavirus 9-valent Vaccine, Recombinant Injection (GARDASIL9), prefilled syringe (lot #Y012508, expiration date: 01-JAN-2027) (dose and frequency reported as 1 dose), for prophylaxis. The administered doses of the vaccine experienced a temperature excursion 0 degree centigrade for 1 hour. No previous temperature excursion was reported. There was no adverse effect reported. No product quality complaint was involved. More
2839816 45 F MI 05/07/2025 HPV9
 MERCK & CO. INC.
Autoimmune disorder, Varicose vein Autoimmune disorder, Varicose vein
autoimmune likened pigmentosis; prominent varicose veins,; black spots all over her tongue; This spo... autoimmune likened pigmentosis; prominent varicose veins,; black spots all over her tongue; This spontaneous report has been received from a health professional regarding a 46-year-old female patient. Information regarding medical history included chickenpox, and shingles, concurrent conditions included allergy to tetracycline, hydro (+) acitamin (VICODIN) and griseofulvin. And concomitant therapies included enzymes, magnesium, fexofenadine (ALLEGRA), Vitamin D, levothyroxine (SYNTHROID) and valacyclovir. On 24-MAY-2024, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant Suspension for injection (GARDASIL 9), for prophylaxis, 0.5 milliliters, intramuscularly (strength, lot number, expiration date, anatomical location not provided) On an unspecified date (reported as a few days after the vaccine was administered), the patient developed varicose veins that became very prominent. The patient followed-up with a Rheumatologist and found she had also developed Autoimmune Likened Pigmentosis (autoimmune disorder). On an unknown date, (also reported as not sure of date but was "pretty soon after developing the symptoms) the rheumatologist prescribed hydroxychloroquine (PLAQUENIL). After starting hydroxychloroquine (PLAQUENIL) the patient then developed black spots all over her tongue (tongue discoloration). After discovering the black spots the Rheumatologist stopped the hydroxychloroquine (PLAQUENIL). At the time of the report, the patient was not recovered from the events. No further treatment is being administered. The causality between the events and the suspect products was unknown. More
2839870 15 CO 05/07/2025 MMR
 MERCK & CO. INC.
 Y000225
No adverse event, Product appearance confusion No adverse event, Product appearance confusion
No additional AE/PQC.; MMR II turned clear after reconstitution; MMR II turned clear after reconstit... No additional AE/PQC.; MMR II turned clear after reconstitution; MMR II turned clear after reconstitutio. HCP is concerned she may have administered a clear colored MMR II to the patient along side the "normal looking yellow/gold colored vaccine that was assumed to be MMR II based on the color.; This spontaneous report was received from a health care professional (HCP) and refers to a 15-year-old patient of unknown gender. The patient's medical history, concurrent conditions, previous drugs reactions or allergies were not reported, concomitant therapies included Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection (VARIVAX) with its reconstituent sterile diluent (MERCK STERILE DILUENT). On 16-Apr-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (valid lot #Y000225, expiration date: 03-Jan-2026)at a dose of 0.5 mL, reconstituted with sterile diluent (BAXTER STERILE DILUENT) solution for injection pre-filled syringe (valid lot #Y020691, expiration date: 10-Nov-2027) (route of administration not provided) for prophylaxis; HCP stated her coworker reconstituted the vaccines in preparation for her to administer, the prepared reconstituted vaccines were given to her to administer to the patient, she administered a clear colored vaccine to the patient that HCP assumed to be Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection (VARIVAX) based on clear color appearance. HCP went to administer the second vaccine but noticed it was also a clear liquid. HCP knows Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), to be a yellow/gold color so she decided to not administer the second prepared clear colored syringe and obtained another prepared Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), syringe with a yellow/gold color liquid. It was unknown what was in either syringe as neither syringe was labeled. HCP was concerned the Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) turned clear after reconstitution and that was why she had 2 clear colored liquid vaccines. HCP was concerned she might have administered a clear colored Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) to the patient alongside the "normal looking yellow/gold colored" vaccine that was assumed to be Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) based on the color (Poor quality product administered, Product colour issue). HCP reported it was unknown if the first vaccine she administered to patient could have been Varicella Virus Vaccine Live (Oka-Merck) lyophilisate and solvent for solution for injection (VARIVAX) or the Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) because they were both clear and unlabeled. No symptoms reported; no additional adverse event (AE) (No adverse event). Follow-up information was received on 25-APR-2025. On 25-APR-2025, the sample was delivered to facility. The sample consisted of a vial matching the reported lot number. HCP reported the sample she returned was not lyophilized and reported it was the defective reconstituted vaccine. HCP reported she took the vaccine from the syringe and was able to put it back into the vials to send. HCP also reported the sterile diluent that she sent in was additional diluent from the lot used to reconstitute. More
2839871 F CA 05/07/2025 PNC21
 MERCK & CO. INC.
 Y013009
Arthralgia, Hypoaesthesia, Joint range of motion decreased, Pain Arthralgia, Hypoaesthesia, Joint range of motion decreased, Pain
less range of motion due to discomfort; radiating pain of R shoulder; radiating pain of R shoulder; ... less range of motion due to discomfort; radiating pain of R shoulder; radiating pain of R shoulder; numbness from shoulder to fingers; less range of motion due to discomfort; Information has been received from the agency Food and Drug Administration (FDA) on 21-APR-2025 and refers to a(n) 51-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions included chronic hip pain. Concomitant medications included gabapentin, paracetamol (TYLENOL) and ibuprofen. On 13-Dec-2024, the patient was vaccinated with the first dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (valid lot #Y013009, expiration date: 17-Nov-2025), administered by Intramuscular route in Right Arm for Prophylaxis. On 03-Jan-2025, the patient adiating pain of R shoulder with numbness from shoulder to fingers. Patient also experiencing less range of motion due to discomfort. Per patient has not seeked medical attention for shoulder pain. referred patientto PCP for follow up. At the reporting time, the patient had not recovered from the events The action taken with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not applicable. The causal relationship between the events and the suspect vaccine was not reported.; Sender's Comments: Priority : 5 , Is case serious : No , Index user : , Index date : 2025-04-21 , MNSC number : , CLIC number : , ESTAR number : , IRMS number : 2825370-1 , Central date : 2025-04-21 , Classification : DMC, Attachment description : Post Marketing Basic , Safety case number : More
2839872 NJ 05/07/2025 MMRV
 MERCK & CO. INC.
 Y014436
No adverse event, Product storage error No adverse event, Product storage error
No additional AEs were reported; The medical assistant is reporting that a patient received improper... No additional AEs were reported; The medical assistant is reporting that a patient received improperly stored vaccine. No additional AEs were reported, no further information provided. Names of vaccines involved (including lot/exp) PROQUAD (y014436 02/22/2026) Temperature and Ti; This spontaneous report has been received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On 15-APR-2025, the patient was vaccinated with improperly stored dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) solution for injection, lot# Y014436, expiration date: 22-FEB-2026 (exact dose, dose number, route of administration and anatomical location were not provided), for prophylaxis (Product storage error). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) solution for injection (lot# and expiry date were not provided). On an unknown date before administration, the vaccine underwent a temperature excursion of 5.5 up to 14.4 Fahrenheit degree for 40 minutes and 14.5 up to 46.4 Fahrenheit degree/15.8 Fahrenheit degree for 10 minutes. There was no previous temperature excursion. No additional adverse event was reported. More
2839873 NJ 05/07/2025 MMRV
 MERCK & CO. INC.
 Y011215
No adverse event, Product storage error No adverse event, Product storage error
No additional AE reported; PROQUAD that experienced temperature excursion was administered to one pa... No additional AE reported; PROQUAD that experienced temperature excursion was administered to one patient; This spontaneous report was received from a/an Consumer or other non health professional and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 10-Apr-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), lot #Y011215, expiration date: 18-Dec-2025, administered for prophylaxis (strength, dose and route of administration were not reported) following temperature excursion occurred in February 2025 (Temperature 6๏ฟฝF to 14๏ฟฝF (7.2F) for 0 hours 20 minutes 0 seconds) (Improper storage of product in use). The vaccine was reconstituted with sterile diluent. No previous temperature excursion. No additional details provided. No additional AE reported (No adverse event). More
2839874 NM 05/07/2025 DTPPVHBHPB
RV5
 MSP VACCINE COMPANY
MERCK & CO. INC.
 U7947AA
2088619
Product storage error; Product storage error Product storage error; Product storage error
No adverse event; HBP reported patient was administered ROTATEQ & VAXELIS during a temperature e... No adverse event; HBP reported patient was administered ROTATEQ & VAXELIS during a temperature excursion. Date of administration was 04/28/2025. No additional details reported. No additional AE reported. No PQC reported. ? Names of vaccines involved (including; This spontaneous report was received from a Health business professional and refers to a identified patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-APR-2025, the patient received a dose of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (VAXELIS), Injection (lot #U7947AA, expiration date: 31-Oct-2026) 0.5 mL (1 dose), and a dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), (lot #2088619, expiration date: 09-Mar-2026) both for prophylaxis, during a temperature excursion of 0๏ฟฝC during 1hour. There were no previous temperature excursions. No additional details reported. No additional AE reported. No PQC reported.; Reporter's Comments: More
2839875 VA 05/07/2025 VARCEL
 MERCK & CO. INC.
 Y014868
No adverse event, Product storage error No adverse event, Product storage error
No symptoms were reported by patient; HCP calling to reporting an administered VARIVAX with TE.; Thi... No symptoms were reported by patient; HCP calling to reporting an administered VARIVAX with TE.; This spontaneous report was received from a Registered Nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions were not reported, and concomitant therapies were not reported. On 29-APR-2025, the patient started therapy with an improper storage of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX REFRIGERATOR STABLE),(dose , route of administration were not reported) (lot #Y014868, expiration date: 03-SEP-2026) with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date were not reported) for prophylaxis )( Product storage error). The administered doses of the vaccine experienced a temperature excursion -10 degree Celsius to 0 degree Celsius for 2 hours 43 minutes and 14 degrees Celsius to -10 degree Celsius (-14 degree Celsius) for 15 hours 6 minutes. It was unspecified if the data was recorded by a data logger. There was no adverse effect reported. No product quality complaint was involved. It was reported that the vaccine did not experience previous temperature excursion. Lot # is being requested and will be submitted if received. More
2839876 F 05/07/2025 RVX
 UNKNOWN MANUFACTURER
 UNK
Myocardial infarction Myocardial infarction
my daughter had a heart attack; This serious case was reported by a consumer via interactive digital... my daughter had a heart attack; This serious case was reported by a consumer via interactive digital media and described the occurrence of heart attack in a female patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis. On an unknown date, the patient received RSV vaccine. On an unknown date, an unknown time after receiving RSV vaccine, the patient experienced heart attack (Verbatim: my daughter had a heart attack) (serious criteria GSK medically significant). The outcome of the heart attack was not reported. It was unknown if the reporter considered the heart attack to be related to RSV vaccine. The company considered the heart attack to be unrelated to RSV vaccine. Additional Information: GSK receipt date: 01-MAY-2025 This case was reported by a patient's parent via interactive digital media. The reporter had a mini stroke after the vaccine and the patient had a heart attack. Patient would not get another one. This case is linked with US2025AMR055150, reported by same reporter.; Sender's Comments: Myocardial infarction is an unlisted event which is considered unrelated to GSK vaccine RSV vaccine. More
2839877 74 F OH 05/07/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Burning sensation, Dermatitis, Erythema, Rash macular Burning sensation, Dermatitis, Erythema, Rash macular
skin inflammation; burning sensation; red; Bumpy; This non-serious case was reported by a consumer v... skin inflammation; burning sensation; red; Bumpy; This non-serious case was reported by a consumer via call center representative and described the occurrence of skin inflammation in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included skin cancer. On an unknown date, the patient received the 1st dose of Shingrix (intramuscular, left arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced skin inflammation (Verbatim: skin inflammation), burning sensation (Verbatim: burning sensation), erythema (Verbatim: red) and swelling (Verbatim: Bumpy). The outcome of the skin inflammation, burning sensation, erythema and swelling were not resolved. It was unknown if the reporter considered the skin inflammation, burning sensation, erythema and swelling to be related to Shingrix. It was unknown if the company considered the skin inflammation, burning sensation, erythema and swelling to be related to Shingrix. Additional Information: GSK Receipt Date: 25-APR-2025 The patient reports on April 25th, 2025, that she got her 1st dose of Shingrix Vaccine about 3 weeks ago. The patient reported that broke out with a skin inflammation on the arms and legs, but it was not like a rash. She reports it was like a burning sensation, and states, it was like a bad sunburn, like blotchy it was red and bumpy. The patient reports it's been 3 weeks and has not resolved. The patient reports some medical history information. No additional event was reported. More
2839878 F 05/07/2025 VARZOS
VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
 UNK
UNK
Influenza A virus test positive, Respiratory syncytial virus infection, Sinusiti... Influenza A virus test positive, Respiratory syncytial virus infection, Sinusitis, Viral diarrhoea; Influenza A virus test positive, Respiratory syncytial virus infection, Sinusitis, Viral diarrhoea More
HPV infection; Influenza A virus subtype H1N1 test positive; Sinusitis; Viral diarrhea; This non-ser... HPV infection; Influenza A virus subtype H1N1 test positive; Sinusitis; Viral diarrhea; This non-serious case was reported by a consumer and described the occurrence of viral diarrhea in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included human papilloma virus infection (HPV reappeared after being cleared for 2 years on most recent pap. (Viral diarrhea)). Previously administered products included Flu vaccine (patient was vaccinated for both flu and covid in the autumn.) and COVID (patient was vaccinated for both flu and covid in the autumn.). On 01-OCT-2024, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On 15-OCT-2024, 14 days after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced viral diarrhea (Verbatim: Viral diarrhea). On 03-DEC-2024, the patient experienced sinusitis (Verbatim: Sinusitis). On 30-JAN-2025, the patient experienced influenza a virus subtype h1n1 test positive (Verbatim: Influenza A virus subtype H1N1 test positive). On 14-FEB-2025, the patient experienced hpv infection (Verbatim: HPV infection). On 30-NOV-2024, the outcome of the viral diarrhea was resolved with sequelae (duration 1 month 15 days). On 08-FEB-2025, the outcome of the influenza a virus subtype h1n1 test positive was resolved (duration 9 days). On 29-MAR-2025, the outcome of the sinusitis was resolved with sequelae (duration 3 months 26 days). The outcome of the hpv infection was not resolved. It was unknown if the reporter considered the viral diarrhea, sinusitis, hpv infection and influenza a virus subtype h1n1 test positive to be related to Shingrix and Shingrix. It was unknown if the company considered the viral diarrhea, sinusitis, hpv infection and influenza a virus subtype h1n1 test positive to be related to Shingrix and Shingrix. Additional Information: GSK receipt date: 28-APR-2025 Patient was vaccinated for both Flu and Covid in the autumn. Patient have never had the flu before but was sick in January. Patient shared a room or bed with an immunocompromised person and they did not get sick. Sinusitis had to be treated by ENT and was ongoing after repeated antibiotics and steroids (systemic and local). At the time of reporting patient was on steroid nasal rinse. HPV reappeared after being cleared for 2 years on most recent pap. (Viral diarrhea). More
2839879 75 M CO 05/07/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 UNK
Influenza like illness, Pain, Skin burning sensation Influenza like illness, Pain, Skin burning sensation
Skin burning sensation; Flu like symptoms; intermittent sharp pain; This non-serious case was report... Skin burning sensation; Flu like symptoms; intermittent sharp pain; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 04-APR-2025, the patient received the 1st dose of Shingrix. On 04-APR-2025, 5 hrs after receiving Shingrix, the patient experienced influenza-like symptoms (Verbatim: Flu like symptoms). On 05-APR-2025, the patient experienced burning sensation skin (Verbatim: Skin burning sensation). In APR-2025, the patient experienced pain (Verbatim: intermittent sharp pain). The outcome of the influenza-like symptoms was unknown and the outcome of the burning sensation skin and pain were not resolved. It was unknown if the reporter considered the influenza-like symptoms, burning sensation skin and pain to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms, burning sensation skin and pain to be related to Shingrix. Additional Information: GSK Receipt Date: 28-APR-2025 The reporter reported that patient received a Shingrix vaccine over 3 weeks ago. He experienced flu like symptoms starting about 5 hours after the injection. By the 2nd day, noticed feeling a skin burn like sunburn under his forearms, biceps, armpits and back. There were no visible signs of change in the appearance of the skin. The skin burn had persisted since that time. It was annoying but not a substantial pain. However, in the last 24 hours patient had experienced a higher level of skin burn, and in one spot a localized, intermittent sharp pain. More
2839880 05/07/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Abdominal discomfort, Herpes zoster Abdominal discomfort, Herpes zoster
broke out; stomach rolls; This non-serious case was reported by a consumer via interactive digital m... broke out; stomach rolls; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. The patient's past medical history included shingles (Patient had chronic shingles). On an unknown date, the patient received the 1st dose of Shingles vaccine. On 27-APR-2025, an unknown time after receiving Shingles vaccine, the patient experienced shingles (Verbatim: broke out) and stomach discomfort (Verbatim: stomach rolls). The outcome of the shingles and stomach discomfort were not resolved. It was unknown if the reporter considered the shingles and stomach discomfort to be related to Shingles vaccine. It was unknown if the company considered the shingles and stomach discomfort to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 27-APR-2025 This case was reported by a patient via interactive digital media. Patient had chronic shingles since 2001. Patient had received the first shot and broke out on the morning of reporting day. Also stated that the pain was horrible, and stomach rolled. This case is linked with case US2025AMR054754, reported by the same reporter.; Sender's Comments: US-GSK-US2025AMR054754:friend case More
2839881 05/07/2025 VARZOS
VARZOS
VARZOS
 UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
UNKNOWN MANUFACTURER
 UNK
UNK
UNK
Extra dose administered, Herpes zoster, Mobility decreased, Pain, Vaccination fa... Extra dose administered, Herpes zoster, Mobility decreased, Pain, Vaccination failure; Extra dose administered, Herpes zoster, Mobility decreased, Pain, Vaccination failure; Extra dose administered, Herpes zoster, Mobility decreased, Pain, Vaccination failure More
Suspected vaccination failure; the last one I get it/ The pain still there; now badly can move; have... Suspected vaccination failure; the last one I get it/ The pain still there; now badly can move; have 3 shots; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a 80-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 3rd dose of Shingles vaccine, the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: the last one I get it/ The pain still there), mobility decreased (Verbatim: now badly can move) and extra dose administered (Verbatim: have 3 shots). The outcome of the vaccination failure was not reported and the outcome of the shingles and mobility decreased were not resolved and the outcome of the extra dose administered was not applicable. It was unknown if the reporter considered the vaccination failure, shingles and mobility decreased to be related to Shingles vaccine, Shingles vaccine and Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine, Shingles vaccine and Shingles vaccine. It was unknown if the company considered the shingles and mobility decreased to be related to Shingles vaccine, Shingles vaccine and Shingles vaccine. Additional Information: GSK Receipt Date: 30-APR-2025 This case was reported by a patient via interactive digital media. The patient had 3 shots of Shingles vaccine and after the last one he/she got it (shingles). The patient reported that the pain was still there and now he/she badly could move. The patient received the three shots of Shingles vaccine, which led to extra dose administered This case was considered as suspected vaccination failure as details regarding time to onset and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding time to onset and laboratory confirmation of disease) is considered unrelated to GSK Shingles vaccine (Dose 1, Dose 2 and Dose 3). More
2839882 05/07/2025 VARZOS
VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
 UNK
UNK
Herpes zoster, Vaccination failure; Herpes zoster, Vaccination failure Herpes zoster, Vaccination failure; Herpes zoster, Vaccination failure
Suspected vaccination failure; I got shingles; This serious case was reported by a consumer via inte... Suspected vaccination failure; I got shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a 71-year-old patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Varicella zoster vaccine (received old vaccine on an unknown date). On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: I got shingles). The outcome of the vaccination failure and shingles were not reported. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. The company considered the vaccination failure to be unrelated to Shingrix and Shingrix. It was unknown if the company considered the shingles to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 30-APR-2025 This case was reported by a patient via interactive digital media. The patient had the old vaccine then the two shots of the new Shingrix vaccine and after that he/she got shingles. It was milder because of having the vaccine but patient still got it at 71. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding time to onset and laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingrix (Dose 1 and Dose 2). More
2839883 05/07/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Muscle disorder Muscle disorder
lost all muscle control; This non-serious case was reported by a consumer via interactive digital me... lost all muscle control; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of muscle disorder in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced muscle disorder (Verbatim: lost all muscle control). The outcome of the muscle disorder was not reported. It was unknown if the reporter considered the muscle disorder to be related to Shingles vaccine. It was unknown if the company considered the muscle disorder to be related to Shingles vaccine. Additional Information: GSK receipt date: 27-APR-2025 This case was reported by a consumer via interactive digital media. The reporter reported that his/her friend who got second shot and experienced lost all muscle control. The reporter mentioned that so what's a person to did. This case had been link with US2025AMR052000, reported by the same reporter. More
2839884 05/07/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Herpes zoster Herpes zoster
got shingles; This non-serious case was reported by a consumer via interactive digital media and des... got shingles; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, immediately after receiving Shingles vaccine, the patient experienced shingles (Verbatim: got shingles). The outcome of the shingles was not reported. It was unknown if the reporter considered the shingles to be related to Shingles vaccine. It was unknown if the company considered the shingles to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 28-APR-2025 This case was reported by a patient via interactive digital media. The reporter said that they did not always work and he/she thought may sometimes trigger the disease, 2 out of 3 friends that took the vaccine got shingles shortly after. One friend (patient) had a light case and the other friend had more severe on her head and forehead. This case is linked with US2025AMR054251, reported by same reporter; Sender's Comments: US-GSK-US2025AMR054251:friend case More
2839885 05/07/2025 VARZOS
 UNKNOWN MANUFACTURER
 UNK
Herpes zoster, Vaccination failure Herpes zoster, Vaccination failure
Suspected vaccination failure; Shingles; This serious case was reported by a consumer via interactiv... Suspected vaccination failure; Shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in unspecified number of patients who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles). The outcome of the vaccination failure and shingles were not reported. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine. The company considered the vaccination failure to be unrelated to Shingles vaccine. It was unknown if the company considered the shingles to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 02-MAY-2025 This case was reported by a consumer via interactive digital media. Reporter reported that big pharmaceutical companies pushing poison (vaccine) and everyone the reporter knew who got their poison (vaccine) got shingles anyway. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: Vaccination failure is a listed event which, due to the following criteria (insufficient information provided about the clinical description, details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of disease) is considered unrelated to GSK vaccine Shingles vaccine. More
2839886 17 F FL 05/07/2025 HEPA
 GLAXOSMITHKLINE BIOLOGICALS
 Z27PB
Incorrect dose administered Incorrect dose administered
17-year-old patient received an adult dose of Havrix; 17-year-old patient received an adult dose of ... 17-year-old patient received an adult dose of Havrix; 17-year-old patient received an adult dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 17-year-old female patient who received HAV (Havrix) (batch number Z27PB, expiry date 27-AUG-2026) for prophylaxis. On 02-MAR-2025, the patient received the 1st dose of Havrix. On 02-MAR-2025, an unknown time after receiving Havrix, the patient experienced adult product administered to child (Verbatim: 17-year-old patient received an adult dose of Havrix) and overdose (Verbatim: 17-year-old patient received an adult dose of Havrix). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-APR-2025 Other HCP reported that on 02nd May 2025, a 17-year-old patient received an adult dose of Havrix, which led to Adult product administered to child and overdose. It was the first dose of the series. More
2839887 61 F GA 05/07/2025 CHIK
CHIK
 VALNEVA USA, INC.
VALNEVA USA, INC.
 24B011
24B011
Bone pain, Chills, Fatigue, Headache, Lethargy; Myalgia, Nausea, Pain, Pyrexia Bone pain, Chills, Fatigue, Headache, Lethargy; Myalgia, Nausea, Pain, Pyrexia
Fever, severe bone pain, muscle aches, severe headache (described as the worst she's had, skele... Fever, severe bone pain, muscle aches, severe headache (described as the worst she's had, skeletal in nature. Teeth throbbing, skull pain, etc), lethargy, chills. Symptoms started on day 7, still continuing on day 10 . Patient reported today that she is starting to feel better, but still has nausea, low grade fever, fatigue. OTC medications not helpful in managing symptoms. More
2839888 4 M MN 05/07/2025 PPV
 MERCK & CO. INC.
 Y009239
Erythema, Rash, Rash erythematous Erythema, Rash, Rash erythematous
Rash up and down his arms and legs, on his back. Pt also had rosy cheeks. Pt's abdomen was c... Rash up and down his arms and legs, on his back. Pt also had rosy cheeks. Pt's abdomen was clear. Rash is smooth and red, not raised. It is not itchy. Mom gave him Benadryl and Tylenol. More
2839889 16 M WV 05/07/2025 MENB
 NOVARTIS VACCINES AND DIAGNOSTICS
 99G34
Erythema, Pyrexia, Swelling Erythema, Pyrexia, Swelling
Reported arm redness and swelling the evening after vaccination. Fever 101F noted 05/07/2025 morning Reported arm redness and swelling the evening after vaccination. Fever 101F noted 05/07/2025 morning
2839890 81 F MN 05/07/2025 COVID19
COVID19
 PFIZER\BIONTECH
PFIZER\BIONTECH
 ME6072
ME6072
Cyanosis, Death, Dyspnoea, Pallor, Pulse absent; Unresponsive to stimuli Cyanosis, Death, Dyspnoea, Pallor, Pulse absent; Unresponsive to stimuli
5/6 evening Resident gotten ready for bed with assist of 1 and when resident laid down on bed becam... 5/6 evening Resident gotten ready for bed with assist of 1 and when resident laid down on bed became SOB and had labored breathing and also became unresponsive. Skin color in face was ashen and purple around lips and nose. 911 was notified. Ambulance arrived and resident was gasping for air and pulse could not be felt. Resident passed away. No adverse events noted prior. More
โœ“
2839891 53 F NY 05/07/2025 PNC20
 PFIZER\WYETH
Chills, Pain, Pyrexia Chills, Pain, Pyrexia
chills, aches, fever for 18 hours chills, aches, fever for 18 hours
2839892 62 F MI 05/07/2025 TDAP
VARZOS
 SANOFI PASTEUR
GLAXOSMITHKLINE BIOLOGICALS
 U8015AA
E3XT9215Y37PS66
Rash; Rash Rash; Rash
Rash Rash
2839893 3 M TX 05/07/2025 PNC13
 PFIZER\WYETH
Extra dose administered Extra dose administered
Patient had vaccines in several facilities per patient's mom. Patient is over vaccinated. Patient had vaccines in several facilities per patient's mom. Patient is over vaccinated.
2839894 3 M TX 05/07/2025 PNC13
 PFIZER\WYETH
Extra dose administered Extra dose administered
Patient had vaccines in several facilities per patient's mom. Patient is over vaccinated. Patient had vaccines in several facilities per patient's mom. Patient is over vaccinated.
2839895 61 F ID 05/07/2025 MMR
 MERCK & CO. INC.
Rash Rash
rash rash
2839896 11 F AL 05/07/2025 HPV9
HPV9
MNQ
MNQ
TDAP
TDAP
VARCEL
VARCEL
 MERCK & CO. INC.
MERCK & CO. INC.
SANOFI PASTEUR
SANOFI PASTEUR
GLAXOSMITHKLINE BIOLOGICALS
GLAXOSMITHKLINE BIOLOGICALS
MERCK & CO. INC.
MERCK & CO. INC.
 Y012508
Y012508
U8361AA
U8361AA
LX494
LX494
Y010045
Y010045
Abdominal pain upper, Feeling hot, Headache, Hyperhidrosis, Nausea; Vomiting; Ab... Abdominal pain upper, Feeling hot, Headache, Hyperhidrosis, Nausea; Vomiting; Abdominal pain upper, Feeling hot, Headache, Hyperhidrosis, Nausea; Vomiting; Abdominal pain upper, Feeling hot, Headache, Hyperhidrosis, Nausea; Vomiting; Abdominal pain upper, Feeling hot, Headache, Hyperhidrosis, Nausea; Vomiting More
Approximately 5 minutes after vaccination administration the patient began to voice complaints of be... Approximately 5 minutes after vaccination administration the patient began to voice complaints of being hot and sweaty, having a headache, stomach ache, nausea and had 2 vomitus episodes. Cool towelette was placed on the patient?s forehead and the patient was provided a receptacle to vomit. Vitals were assessed, and they were as follow: B/P 89/56, HR 67bpm and respirations 14bpm. After the vomitus episode the patient was taken to an examination room to lie down and states she felt better after vomiting, voiced she is hungry and was provided a pack of peanut butter crackers and water. The patient ate the crackers with no complications or issues noted. Patient was observed for approx. 15 minutes thereafter with no issues, signs of adverse reactions, anaphylaxis or complications noted prior to departure. Vital signs at departure: B/P 95/57, heart rate 64bpm, respirations 14bpm. More
2839897 F FL 05/07/2025 HEPA
 GLAXOSMITHKLINE BIOLOGICALS
Incorrect dose administered Incorrect dose administered
Administration of Havrix adult dose to a 17 year-old patient; received the adult dose of Havrix; Thi... Administration of Havrix adult dose to a 17 year-old patient; received the adult dose of Havrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 17-year-old female patient who received HAV (Havrix adult) for prophylaxis. On an unknown date, the patient received the 1st dose of Havrix adult. On an unknown date, an unknown time after receiving Havrix adult, the patient experienced adult use of a child product (Verbatim: Administration of Havrix adult dose to a 17 year-old patient) and overdose (Verbatim: received the adult dose of Havrix). The outcome of the adult use of a child product and overdose were not applicable. Additional Information: GSK Receipt Date: 28-APR-2025 The pharmacist reported that a month ago on March 2025, a 17 year-old patient received the adult dose of Havrix as a first dose, which led to adult use of a child product and overdose. Patient was going to the military so she had been taking all vaccination again, such as IPV, Varicella, etc. The Healthcare professional advised her doctor about this procedure. No adverse effects had been reported to date. The Vaccine Administration Facility is the same as Primary Reporter. More
2839898 57 F CA 05/07/2025 MNQ
 NOVARTIS VACCINES AND DIAGNOSTICS
 Z92L4
Wrong product administered Wrong product administered
The patient was administered the incorrect vaccine (Menveo). The member should have received the Men... The patient was administered the incorrect vaccine (Menveo). The member should have received the Men-B (Bexsero) on 4/29/2025. The member did receive the correct vaccine on 5/2/2025 (Men-B (Bexsero)--Lot#52N4S/NDC#58160-976-02, exp date 11/30/2027) at facility. More
2839899 77 F GA 05/07/2025 HEPAB
 GLAXOSMITHKLINE BIOLOGICALS
 M4B34
Lymphadenopathy Lymphadenopathy
2 days after receiving vaccine, the lymph nodes in the neck on the left side (side vaccine was admin... 2 days after receiving vaccine, the lymph nodes in the neck on the left side (side vaccine was administered) started swelling and being sore. This lasted for another 2-3 days then resolved. More
2839900 71 F OH 05/07/2025 VARZOS
 GLAXOSMITHKLINE BIOLOGICALS
 93kk4
Erythema, Immediate post-injection reaction, Pain, Swelling Erythema, Immediate post-injection reaction, Pain, Swelling
pain, redness, size of a softball swelling immediately after injection pain, redness, size of a softball swelling immediately after injection
2839901 61 M FL 05/07/2025 PNC20
 PFIZER\WYETH
 LX4483
Injection site erythema, Rash, Urticaria Injection site erythema, Rash, Urticaria
Pt developed redness at the site of injection. 24 hours later, He had generalized hives and a rash. ... Pt developed redness at the site of injection. 24 hours later, He had generalized hives and a rash. No SOB or other respiratory symptoms. He has prior h/o allergies. More
2839902 11 M NY 05/07/2025 MNQ
 NOVARTIS VACCINES AND DIAGNOSTICS
 DL4YY
Fatigue, Injection site erythema, Injection site warmth Fatigue, Injection site erythema, Injection site warmth
approximately a softball size circular red and warm area around injection site with fatigue approximately a softball size circular red and warm area around injection site with fatigue
2839903 0.33 M MN 05/07/2025 RV5
 MERCK & CO. INC.
Discomfort, Haematochezia, Intussusception Discomfort, Haematochezia, Intussusception
Several currant-jelly bloody stools 18-24 hours after vaccine, transient discomfort. Suspect self-re... Several currant-jelly bloody stools 18-24 hours after vaccine, transient discomfort. Suspect self-resolved intussusception. More
2839904 72 F 05/07/2025 COVID19
 PFIZER\BIONTECH
 3046714
Neck pain Neck pain
Severe neck pain approximately 3 days after neck pain lasting 3 days, pt went to hospital to treat p... Severe neck pain approximately 3 days after neck pain lasting 3 days, pt went to hospital to treat pain, was given prednisone and that seemed to alleviate the pain More
2839905 11 M FL 05/07/2025 HPV9
 MERCK & CO. INC.
 y012776
Asthenia, Dizziness, Pyrexia Asthenia, Dizziness, Pyrexia
MOC states Pt. is having weakness, fever and dizziness. Ondansetron was given as treatment. MOC states Pt. is having weakness, fever and dizziness. Ondansetron was given as treatment.
2839906 72 F TX 05/07/2025 COVID19
 MODERNA
 031A32A
Blood test, Impaired healing, Injection site pain Blood test, Impaired healing, Injection site pain
pt says her right arm has a sore around the injection site that never healed. She has been to severa... pt says her right arm has a sore around the injection site that never healed. She has been to several doctors since then and they have never been able to help her with it. The last doctor that she saw has ordered her some blood work to help diagnose the issue with her arm not healing. She is waiting on her results to come back. More
2839907 17 F MN 05/07/2025 HPV9
MENB
MNQ
 MERCK & CO. INC.
PFIZER\WYETH
SANOFI PASTEUR
 Y018398
HP9987
U8194AA
Pallor, Syncope; Pallor, Syncope; Pallor, Syncope Pallor, Syncope; Pallor, Syncope; Pallor, Syncope
Patient had syncopal episode after receiving vaccines. Patient was seated in office room chair in cl... Patient had syncopal episode after receiving vaccines. Patient was seated in office room chair in clinic room. HPV and Medquadfi were administered first in left arm and then Trumenba was administered in right arm and patient had the episode. Episode lasted approximately 5 seconds; head slouched down and eyes closed. Immediately patient sat up startled and opened eyes. Patient did not fall from chair. Patient was pale, but alert. Provider notified and patient observed for additional 15 minutes. Patient was given water. Patient was okay and ambulated. More
2839908 19 F MA 05/07/2025 HPV9
 MERCK & CO. INC.
Headache, Hypersomnia, Mood altered Headache, Hypersomnia, Mood altered
hypersomnolence, headache, mood changes hypersomnolence, headache, mood changes
2839909 59 F MI 05/07/2025 PNC20
 PFIZER\WYETH
 LX4484
Injection site erythema, Injection site warmth Injection site erythema, Injection site warmth
Patient developed redness and warmth below the injection site 4 days after administration Patient developed redness and warmth below the injection site 4 days after administration
2839910 11 M TX 05/07/2025 COVID19
 PFIZER\BIONTECH
 MD3414
Product administered to patient of inappropriate age Product administered to patient of inappropriate age
pt came for well check up and was accidentally given 12 and up Covid age vaccine instead of 4- 11 ye... pt came for well check up and was accidentally given 12 and up Covid age vaccine instead of 4- 11 years More
2839911 0.25 F CO 05/07/2025 RV5
 MERCK & CO. INC.
 Y014320
Product administered to patient of inappropriate age Product administered to patient of inappropriate age
When discussing vaccines to be given, this RN noted in the Registry that rotavirus was not listed in... When discussing vaccines to be given, this RN noted in the Registry that rotavirus was not listed in the recommended vaccines. The note at the bottom of the recommendation list states, "please do not rely soley on the Recommender to forecast immunizations." Upon looking at the number of days old listed in Epic, this RN noted "(85 day old)" and attempted to calculate age based on days old. Based on 85 day old status, pt would be 12 weeks old. Discussed with CPNP-PC and PA-C if there would be an indication of why a pt wouldn't be able to receive the vaccine at approx 12 weeks with recommendation starting prior to 15 weeks old. None noted when asked. Looked up and printed off CDC recommendation for rotavirus, highlighted 15 week limit, printed off Rotavirus VIS report for MOC and highlighted 15 week limit. Discussed with Dr., PA-C, and CPNP-PC age less than 15 weeks and okay for pt to receive rotavirus. Dr. in agreement and verbally gave order to be put into Epic for rotavirus. This RN charted giving rotavirus prior to going into room and sent vaccine to Registry to verify okay to receive and that the immunization would not be flagged as inappropriate prior to administration. Upon refreshing registry, valid first dose documented. When entering room to administer vaccines, relayed all vaccines to be given and gave VIS printout of all vaccines to be given. Discussed time frame and age with MOC, relayed no pressure to receive rotavirus if not comfortable. MOC verbalized okay to give, this RN showed vaccine, manufacturer, expiration date and administered rotavirus along with other vaccines ordered. After finished charting, this RN rechecked date given and birth date to realize that pt is 17 weeks old based on birth date. RN reported to Dr. and Director of Nursing. More
2839912 1 F IL 05/07/2025 MMR
VARCEL
 MERCK & CO. INC.
MERCK & CO. INC.
 Y014096
Z002625
Rash, Serum sickness; Rash, Serum sickness Rash, Serum sickness; Rash, Serum sickness
Received MMMR & Varicella on 4/24/25, developed serum sickness like reaction 9 days later on 5/3... Received MMMR & Varicella on 4/24/25, developed serum sickness like reaction 9 days later on 5/3/25. No exposure to suggest other trigger - like no medications, no infectious symptoms prior to onset of reaction. Rash consistent with serum sickness, not a typical MMR rash. More
2839913 65 F 05/07/2025 MMR
 MERCK & CO. INC.
 Y009430
Product preparation issue Product preparation issue
Nurse did not reconstitute and gave only the diluent. She realized before the patient left. Acquir... Nurse did not reconstitute and gave only the diluent. She realized before the patient left. Acquired additional diluent, reconstituted correctly and gave the vaccine. More
๐Ÿ“‹ Privacy Policy & Data Disclaimer